SIGA - SIGA Technologies, Inc.
Chart Events
Commodity Channel Index
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 5.99 |
| Open | 6.01 |
| Bid | 5.99 x 900 |
| Ask | 6.35 x 900 |
| Day's Range | 5.90 - 6.04 |
| 52 Week Range | 3.96 - 6.20 |
| Volume | 176,674 |
| Avg. Volume | 271,289 |
| Market Cap | 486.284M |
| Beta (5Y Monthly) | 0.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.24 |
| Earnings Date | Aug 04, 2020 - Aug 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- Market Digest: CBOE, EBS, NSC, TWTR, AZN, GD, ITW, LAZ, SWKS, F
- Analyst Report: Emergent BioSolutions Inc
- Thomson Reuters StreetEvents
Edited Transcript of SIGA earnings conference call or presentation 6-May-20 8:30pm GMT
Q1 2020 SIGA Technologies Inc Earnings Call
- Motley Fool
SIGA Technologies Inc. (SIGA) Q1 2020 Earnings Call Transcript
For a discussion of factors that could cause results to differ, please see the company's filings with the Securities and Exchange Commission including, without limitation, the company's annual report on Form 10-K for the year ended December 31, 2019, and its subsequent reports on Form 10-Q and Form 8-K. I will now turn the conference over to Phil Gomez, chief executive officer of SIGA. Today, I'm joined by Dan Luckshire, our CFO; and Dr. Dennis Hruby, our chief scientific officer. On this call, Dan will be providing an update of our Q1 financial results, recent orders for TPOXX from the Canadian military in BARDA and expectations related to these orders.
- GlobeNewswire
SIGA Technologies, Inc. Reports Financial Results for the First Quarter of 2020
- Company Recently Announced Exercise of Contract Options Totaling $101.3 million - - Corporate Update Conference Call Today at 4:30 PM ET - NEW YORK, May 06, 2020 -- SIGA.
- GlobeNewswire
SIGA Announces BARDA Exercise of Contract Options Valued at $101.3 Million for the Procurement of Oral TPOXX®
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced the exercise of options under its 2018 Biomedical Advanced Research and Development Authority (BARDA) contract (“19C BARDA Contract”) worth a total of approximately $101.3 million for the procurement of oral TPOXX for the treatment of smallpox (tecovirimat). Deliveries of oral TPOXX to maintain national preparedness under these option exercises are expected to start in the second quarter of 2020 and be completed by April 2021. With the above-mentioned exercise of options, all procurement options under CLIN 9 (contract line item number 9) of the 19C BARDA Contract have been exercised.
- GlobeNewswire
SIGA Technologies to Host Business Update Call on May 6, 2020 after Release of First Quarter Financial Results
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Wednesday, May 6, 2020. Participating on the call will be Dr. Phil Gomez, Chief Executive Officer, Daniel Luckshire, Chief Financial Officer, and Dr. Dennis Hruby, Chief Scientific Officer. Participants may also access the call, by dialing (877) 407-6184 for domestic callers or (201) 389-0877 for international callers.
- GlobeNewswire
SIGA Announces Award of First International Contract for Oral TPOXX® with Purchase by the Canadian Department of National Defence
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the Canadian Department of National Defence (CDND) has awarded a contract to Meridian Medical Technologies, Inc. (“Meridian”, a Pfizer Company) (Canadian Contract), in which it will purchase up to 15,325 courses of oral TPOXX (tecovirimat) over four years for a total value of $14.3 million, with an initial purchase of 2,500 courses for $2.3 million. “The current COVID-19 pandemic has reminded us all that preparedness with medical countermeasures is critical for responding effectively to any infectious disease outbreak,” said Dr. Phil Gomez, CEO of SIGA Technologies.
- Thomson Reuters StreetEvents
Edited Transcript of SIGA earnings conference call or presentation 5-Mar-20 9:30pm GMT
Q4 2019 SIGA Technologies Inc Earnings Call
- Simply Wall St.
Did Business Growth Power SIGA Technologies's (NASDAQ:SIGA) Share Price Gain of 117%?
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
- GlobeNewswire
SIGA Technologies, Inc. Reports Financial Results for Fiscal Year 2019
- Announces Expectations for Product Delivery to BARDA -- Announces $50 Million Share Repurchase Program -- Corporate Update Conference Call Today at 4:30 PM ET - NEW YORK,.
- ACCESSWIRE
SIGA Technologies, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 5, 2020 / SIGA Technologies, Inc. (SIGA) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 5, 2020 at 4:30 PM Eastern ...
- GlobeNewswire
SIGA Announces Collaboration with Turnstone Biologics
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it entered into a collaboration with Turnstone Biologics to provide TPOXX® (tecovirimat) in connection with Turnstone’s proprietary SKV vaccinia oncolytic immunotherapy platform. The collaboration will provide Turnstone with access to SIGA’s TPOXX oral antiviral capsules for use if required in future clinical programs. “TPOXX has potential as a new tool to support the adoption of oncolytic vaccinia virus immunotherapies, including those being developed by Turnstone,” said Dr. Phil Gomez, CEO of SIGA.
- GlobeNewswire
SIGA to Host Business Update Call on March 5, 2020 after Release of Year End Financial Results
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, March 5, 2020 after release of year end financial results. Participating on the call will be Dr. Phil Gomez, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. Participants may also access the call, by dialing (877) 407-6184 for domestic callers or (201) 389-0877 for international callers.
- Insider Monkey
Hedge Funds Are Betting On SIGA Technologies Inc. (SIGA)
After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of September 30th. The results of that effort will be put on display in this article, as […]
- GlobeNewswire
SIGA Announces Canadian Department of National Defence Intent to Purchase Up To 15,325 Courses of Oral TPOXX®
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the Canadian Department of National Defence (CDND) has issued an advanced contract award notice (ACAN), indicating that the CDND intends to purchase up to 15,325 courses of oral TPOXX (tecovirimat) over four years as specified in the ACAN, with an initial purchase of 2,500 courses. The ACAN is required to remain open for at least 15 days, during which time a potential alternative supplier may submit a competing Statement of Capabilities.
- GlobeNewswire
SIGA Announces Canadian Release of the Advanced Contract Award Notice to Support Regulatory Filing for Oral TPOXX®
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the Canadian Department of National Defence (CDND) has issued an advanced contract award notice (ACAN), indicating that it intends to award a contract to fund regulatory filing with Health Canada for approval of oral TPOXX®. The ACAN is required to remain open for approximately 15 days, during which time a potential alternative supplier who meets the ACAN requirements for a smallpox anti-viral therapy that has been approved by national regulatory authority may submit a competing Statement of Capabilities.
- Simply Wall St.
Do Institutions Own SIGA Technologies, Inc. (NASDAQ:SIGA) Shares?
The big shareholder groups in SIGA Technologies, Inc. (NASDAQ:SIGA) have power over the company. Insiders often own a...
- Insider Monkey
Here is What Hedge Funds Think About SIGA Technologies Inc. (SIGA)
We can judge whether SIGA Technologies Inc. (NASDAQ:SIGA) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their lead into their best […]
- GlobeNewswire
SIGA Technologies CEO to Speak at NCT Asia Conference on October 23, 2019
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, Chief Executive Officer, will be a speaker at the Non-Conventional Threats (NCT) Asia Conference in Kuala Lumpur, Malaysia. Dr. Gomez will present on “Medical Preparedness for Chemical, Biological, Radiological and Nuclear Defense (CBRNe) Events” at 4:00 p.m. Malaysia Time on Wednesday, October 23, 2019.
- GlobeNewswire
SIGA Completes Clinical Studies for IV Formulation of TPOXX®, NDA to be Submitted in 2020
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has reached concurrence with the US Food and Drug Administration (FDA) that no further clinical studies will be required for the IV formulation of TPOXX (tecovirimat), and SIGA anticipates filing the New Drug Application (NDA) for this formulation in 2020. Given that the efficacy of TPOXX was previously established in animal models used to support the development and approval of the oral formulation, the FDA will not require additional efficacy data to support the NDA for the IV formulation.
- GlobeNewswire
SIGA to Present at the Cantor Fitzgerald Global Healthcare Conference on October 3, 2019
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, SIGA’s Chief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference at 3:00 p.m. EDT on Thursday, October 3, 2019 in New York. SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness.
- GlobeNewswire
SIGA Technologies CSO to Speak at The 13th CBRNe Protection Symposium on September 25, 2019
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Dennis E. Hruby, the Company’s Chief Scientific Officer, will be a speaker at the 13th Chemical, Biological, Radiological, Nuclear, and Explosive materials (CBRNe) Protection Symposium in Malmö, Sweden. Dr. Hruby will deliver a presentation titled “TPOXX® for the Treatment of Smallpox” at 4:20 P.M. Central European Summer Time on Wednesday, September 25, 2019. “I am pleased to have the opportunity to share information about the potential role that TPOXX could play in addressing a smallpox outbreak with global colleagues in the field of bio-preparedness,” said Dr. Hruby.
- GlobeNewswire
SIGA to Present at the 14th Annual Wells Fargo Securities Healthcare Conference on September 5, 2019
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, SIGA’s Chief Executive Officer, will participate in an analyst-led fireside chat at the 14th Annual Wells Fargo Securities Healthcare Conference at 3:40 p.m. EDT on Thursday, September 5, 2019 in Boston. SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness.
- GlobeNewswire
SIGA Awarded Department of Defense Contract to Develop Expanded Indication for TPOXX® as Post-Exposure Prophylactic for Smallpox
As previously announced, SIGA is already working with the U.S. Army Medical Research Institute of Infectious Disease on animal studies to evaluate the efficacy of TPOXX as a potential PEP therapy for smallpox. The use of TPOXX for PEP could provide significant potential benefit in the event of a smallpox outbreak. While vaccines would play an important role in containing the spread of smallpox, the vaccines are only effective if administered prior to infection or no later than four days after infection.
- Insider Monkey
Hedge Funds Have Never Been This Bullish On SIGA Technologies Inc. (SIGA)
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the first quarter, which unveil their equity positions as of March 31. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
- GlobeNewswire
SIGA Technologies CEO to Speak at NCT Europe on June 27, 2019
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, Chief Executive Officer, will be a speaker at the Non-Conventional Threats (NCT) Europe Conference in Vienna, Austria. Dr. Gomez will present on “Medical Preparedness for Chemical, Biological, Radiological and Nuclear Defense (CBRNe) Incidents” at 8:30 A.M. Central European Summer Time on Thursday, June 27, 2019. SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market.
